Neuropsychiatric side effects of intrathecal ziconotide;Efectos adversos neuropsiquiátricos del ziconotide intratecal

Revista de Neurologia

Volumn 52, Issue 1, 2011, Pages 61-63

  Ayuga Loro, Fernando ^a   Brocalero Camacho, Ángela ^a   Quintas López, M Visitación ^a   Cabrera Feria, José R ^a  

^a HOSPITAL NACIONAL DE PARAPLÉJICOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

OMEGA CONOTOXIN MVIIA;

HUMAN; LETTER; PSYCHOPATHY;

EID: 79952257864     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5201.2010475     Document Type: Letter

References (9)

1. Villanueva-Pérez VL, Asensio-Samper JM, Fabregat- Cid G, Monserrat-Ripoll C, De Andrés-Ibáñez JA. Mielitis transversa: tratamiento del dolor. Rev Neurol 2010; 50: 318-9.
2. Food & Drug Administration. Prialt label NDA no. 021060. URL: http://www.fda.gov/cder/foi/label/2004/021060lbl.pdf. [04.11.2009].
3. European Medicines Agency. Ziconotide (Prialt). Código ATC: N02BG08. Ficha técnica del medicamento. URL: http://www.ema.europa.eu/ humandocs/PDFs/EPAR/Prialt/emea-combined-h551es.pdf. [04.11.2009].
4. Rauck RL, Wallace MS, Leong MS, Minehart M, Webster LR, Charapata SG, et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage 2006; 31: 393-406.
5. Staats PS, Yearwood T, Charapata SG, Presley RW, Wallace MS, Byas-Smith M, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 2004; 291: 63-70. (Pubitemid 38040536)
6. Wallace MS, Charapata SG, Fisher R, Byas-Smith M, Staats PS, Mayo M, et al. Intrathecal ziconotide in the treatment of chronic non-malignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation 2006; 9: 75-86.
7. Collins R, Lieberburg I, Ludington E, Howard R. Effectiveness of intrathecal ziconotide in multiple pain etiologies: a meta-analysis of three controlled trials [abstract]. Pain Med 2005; 6: 195.
8. Wallace MS, Kosek PS, Staats P, Fisher R, Schultz DM, Leong M. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. Pain Med 2008; 9: 271-81. (Pubitemid 351467884)
9. Webster LR, Fakata KL, Pharm D, Charapata S, Fisher R, MineHart M. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain. Pain Med 2008; 9: 282-90. (Pubitemid 351467885)